LUND, SWEDEN--(Marketwire - April 17, 2012) -
Active Biotech's Annual Report 2011 (in Swedish) is now available for
download
at www.activebiotech.com.
The Annual Report will only be digitally distributed.
Lund, April 17, 2012
Active Biotech AB (publ)
Tomas Leanderson
President & CEO
Active Biotech AB (NASDAQ OMX NORDIC: ACTI) is a biotechnology company with
focus on autoimmune/inflammatory diseases and cancer. Projects in or
entering
pivotal phase are laquinimod, an orally administered small molecule with
unique
immunomodulatory properties for the treatment of multiple sclerosis, TASQ
for
prostate cancer as well as ANYARA for use in cancer targeted therapy,
primarily
of renal cell cancer. In addition, laquinimod is in Phase II development
for
Crohn's and Lupus. Further projects in clinical development comprise the
two
orally administered compounds, 57-57 for Systemic Sclerosis and
RhuDex® for
RA. Please visit http://www.activebiotech.com for more information.
Active Biotech AB (Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund
Tel: +46 46 19 20 00
Fax: +46 46 19 11 00
Active Biotech is obligated to publish the information contained in this
press
release in accordance with the Swedish Securities Market Act. This
information
was provided to the media for publication on April 17, 2012, at 10:00
a.m.
Annual Report 2011 Active Biotech AB (publ):
http://hugin.info/1002/R/1602829/506506.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Active Biotech via Thomson Reuters ONE
[HUG#1602829]
